DOD Neurofibromatosis, Clinical Trial Award | W81XWH 21 NFRP CTA

Opportunity Information: Apply for W81XWH 21 NFRP CTA

The Department of Defense Neurofibromatosis Research Program (NFRP) Clinical Trial Award is a discretionary funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that is meant to move neurofibromatosis (NF) research into patient-focused testing quickly. The central purpose of this award is to support the rapid launch and execution of clinical trials that could meaningfully change how NF is treated or managed, with an emphasis on studies that have clear potential for real-world clinical impact rather than purely exploratory laboratory work.

This award is specifically aimed at funding clinical trials across a wide range of designs and development stages. On the early end, applicants can propose small proof-of-concept studies such as pilot trials, first-in-human evaluations, or phase 0 efforts intended to demonstrate feasibility, establish initial safety signals, explore dosing or delivery, or generate data that helps shape the design of a later, more definitive trial. On the more advanced end, the program can also support larger-scale trials designed to determine efficacy in appropriate NF patient populations, meaning studies that are built to answer whether an intervention actually works for clinically meaningful outcomes.

The types of interventions and trial topics that fit the program are broad, as long as they are tied to improving NF care. Trials may evaluate promising new products, pharmacologic agents including drugs or biologics, medical devices, clinical guidance approaches, and emerging methods or technologies relevant to NF treatment or management. In practical terms, this creates room for both therapeutic testing and studies that could improve how patients are monitored, how clinicians make decisions, or how care is delivered, provided the project is structured as a clinical trial and is positioned to produce actionable evidence.

Administratively, the opportunity is listed as Funding Opportunity Number W81XWH 21 NFRP CTA under the Department of Defense. It allows funding through either a grant or a cooperative agreement mechanism, which signals that some awards may involve more active programmatic involvement from the funder depending on the specifics of the project. The activity category is Science and Technology and other Research and Development, with CFDA number 12.420. Eligibility is described as unrestricted, meaning it is broadly open to many entity types, subject to any additional eligibility clarifications that would have been provided in the full announcement text.

The opportunity was created on April 30, 2021, with an original application closing date of July 22, 2021. The listing indicates an expected number of awards of 1. The award ceiling is shown as 0, which typically means the cap was not specified in the summary field and would need to be confirmed in the full solicitation documents or program guidance rather than interpreted as literally zero available funding.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Neurofibromatosis, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 30, 2021.
• Applicants must submit their applications by Jul 22, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 NFRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: